1-(2-(2',3',5'-trimethyl-4'-acetoxyphenoxy))ethyl piperazine | 199468-15-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 1-(2-(2',3',5'-trimethyl-4'-acetoxyphenoxy))ethyl piperazine
• 英文别名: [2,3,6-Trimethyl-4-(2-piperazin-1-ylethoxy)phenyl] acetate
• CAS: 199468-15-0
• 化学式: C₁₇H₂₆N₂O₃
• 分子量: 306.405
• InChiKey: LKCQGPWDUYVMJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  50.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-t-Butylcarbonyloxy-4-(2-(2', 3', 5'-trimethyl-4'-acetoxyphenoxy))ethyl piperazine 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以98%的产率得到1-(2-(2',3',5'-trimethyl-4'-acetoxyphenoxy))ethyl piperazine
  参考文献：
  名称：

  Arylalkylpiperazine compounds as antioxidants

  摘要：

  本发明揭示了芳基烷基哌嗪化合物（1），其中B是芳基或可选取代芳基；R1是羟基；R2和R3相同或不同，且独立地选自氢或C1-3烷基；m为0、1或2；D为原子连接链，可以选择性地取代，且链中含有1至8个原子；E为酚类抗氧化剂基团或相应的氨基衍生物，其中酚羟基被氨基取代。这些化合物既具有自由基清除活性，又具有抑制兴奋性氨基酸活性的作用。本发明的某些化合物还显示出与电压敏感型钠通道的亲和力。

  公开号：

  US06232314B1

文献信息

• ARYLALKYLPIPERAZINE COMPOUNDS AS ANTIOXIDANTS
  申请人：MONASH UNIVERSITY

  公开号：EP0901469B1

  公开（公告）日：2003-08-27
• NOVEL HETEROCYCLIC AMIDE DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS
  申请人：Aventis Pharmaceuticals Inc.

  公开号：EP1361875A2

  公开（公告）日：2003-11-19
• US6232314B1
  申请人：——

  公开号：US6232314B1

  公开（公告）日：2001-05-15
• [EN] NOVEL HETEROCYCLIC AMIDE DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS<br/>[FR] NOUVEAUX DERIVES HETEROCYCLIQUES D'AMIDES ET LEUR UTILISATION COMME LIGANDS DU RECEPTEUR DE LA DOPAMINE D3
  申请人：AVENTIS PHARMA INC

  公开号：WO2002066469A2

  公开（公告）日：2002-08-29

  The invention relates to heterocyclic substituted amide derivatives of formula (I) that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D3 receptors.